AzTrials
AzTrials

Cardiovascular DiseasesNCT07124949

Chinese Migrant Population Health Cohort

An observational study of Cardiovascular Diseases and Metabolic Disorders, run by Jinwei Tian at 1 site in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The Chinese Migrant Population Health Cohort is a prospective, multi-center study jointly initiated by Professor Yong Ji, President of Harbin Medical University, and Academician Guoqiang Chen, President of Hainan Medical University, in collaboration with regional partners. Read more about this study

Who is it for?
Ages 60 to 120 yearsHealthy volunteers can take part
How many people
26,000 participants
Where
1 siteChina
Study dates
23 Jul 2025to 30 Apr 2030
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 60 to 120 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: The study will enroll community-dwelling adults aged ≥60 years from Harbin (cold region) and Hainan (tropical region), China. Four groups will be included: 1. Winter Migrant Group: ~5,000 Harbin residents who habitually migrate to Hainan during the cold season for ≥2 months each time, with ≥2 consecutive years of such migration and plans to continue; 2. Summer Migrant Group: ~1,000 Hainan residents who habitually migrate to Harbin during the hot season for ≥2 months, with similar migration history and plans; 3. Cold-Region Resident Group: ~10,000 Harbin residents, including matched controls for migrant groups and randomly selected residents, with no >2 months residence outside Harbin in the past 5 years; 4. Tropical-Region Resident Group: ~10,000 Hainan residents with similar matching criteria and residency requirements. All participants must be able to communicate, perform daily activities independently, consent to long-term follow-up, and provide biospecimens.

Who may be able to join

  • Permanent residents of Harbin or Hainan who will continue to reside in Harbin or Hainan for the next 5 years.
  • Baseline age ≥60 years, with basic communication and comprehension abilities.
  • No confirmed diagnosis of end-stage major organic diseases (e.g., advanced heart failure, advanced liver failure, advanced kidney failure, malignant tumors).
  • Able to perform activities of daily living independently and capable of completing questionnaires and physical examinations.
  • Willing to participate in the study, provide written informed consent, accept long-term follow-up, and provide biological specimens.

Who cannot join

  • Occurrence of life-threatening acute events (e.g., myocardial infarction, acute heart failure, stroke) within the past 30 days.
  • Currently receiving chronic treatment with antiviral drugs (e.g., for HIV) or antipsychotic medications.
  • Presence of moderate to severe cognitive impairment preventing survey completion or follow-up cooperation.
  • Current acute infectious diseases such as influenza or fever.
  • Simultaneous participation in other interventional clinical studies.
  • Refusal to sign informed consent or unwillingness to provide biological specimens.
  • Any other condition deemed unsuitable for study participation by the investigators based on overall assessment.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Jinwei Tian, Ph.D. contact

+86 151 1451 8233

tianjinwei@hrbmu.edu.cn

Cheng Jin, Ph.D. contact

+86 153 13298872

jinch@hrbmu.edu.cn

China1 site, 1 recruiting

  • Harbin Medical University

    Harbin, Heilongjiang, 150086,

    Xizheng Wang, Doctor, +86 451 8660 5225, cmphc@hrbmu.edu.cn

    Recruiting

Other trials in China

About this study

The Chinese Migrant Population Health Cohort is a prospective, multi-center study jointly initiated by Professor Yong Ji, President of Harbin Medical University, and Academician Guoqiang Chen, President of Hainan Medical University, in collaboration with regional partners. It targets older adults (≥60 years) who engage in seasonal migration between cold (Heilongjiang) and tropical (Hainan) regions. The primary objective is to investigate cardiovascular and metabolic disease risks, underlying biological and environmental mechanisms, and effective preventive strategies in this unique population.

Participants are recruited from both origin and destination sites and undergo standardized baseline assessments, including questionnaires, physical examinations, medical imaging, biospecimen collection (blood, stool, hair, nails), and environmental exposure monitoring. Longitudinal follow-up includes periodic reassessments, remote monitoring, and data linkage with hospital information systems to capture health outcomes.

Read more

The study aims to:

Define migration-related health risk profiles and disease phenotypes.

Elucidate biological and environmental mechanisms influencing disease onset and progression.

Develop AI-driven risk prediction models and evaluate targeted interventions through nested randomized controlled trials.

Translate findings into clinical guidelines and scalable cross-regional health management models.

This is the first cohort in China to systematically investigate the health impacts of seasonal migration in older adults. By integrating epidemiology, multi-omics, environmental data, and health policy translation, the study seeks to improve continuity of care, strengthen climate adaptation, and promote healthy ageing.

Being tested
No intervention
Keywords
Cardiovascular Diseases, Metabolic Diseases, Geriatrics, Migration, Climate Change, Health Promotion
Medical subject headings
Cardiovascular Diseases, Metabolic Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • No interventionOther

    no intervention

Study groups in NCT07124949
Study groupRoleWhat they receive
Winter Migrant GroupNo Intervention
Receives: Other: No intervention
Summer Migrant GroupNo Intervention
Receives: Other: No intervention
Cold-Region Resident Groupno Intervention
Receives: Other: No intervention
Tropical-Region Resident Groupno Intervention
Receives: Other: No intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants Experiencing First Major Cardiovascular Event

    First occurrence of myocardial infarction, stroke (ischemic or hemorrhagic), or cardiovascular death, confirmed through hospital records, death registries, and adjudication committee review.

    Measured: Up to 5 years from baseline

Secondary outcomes (5)

  1. Number of Participants with New-Onset Metabolic Disorders

    New-onset type 2 diabetes mellitus, dyslipidemia, or obesity as defined by standard clinical and laboratory criteria.

    Measured: Up to 5 years from baseline

  2. Number of Deaths from Any Cause

    Death from any cause, verified through official death certificates and hospital records.

    Measured: Up to 5 years from baseline

  3. Changes in Cardiometabolic Risk Factors

    Longitudinal changes in blood pressure, fasting glucose, HbA1c, lipid profile, BMI, waist circumference, and body composition.

    Measured: Baseline, 2 years, 4 years

  4. Change in EQ-5D Quality of Life Score from Baseline

    Changes in validated quality-of-life scales (e.g., EQ-5D).

    Measured: Baseline, 2 years, 4 years

  5. Change in Cognitive Function Score (MoCA) from Baseline

    Mean change in Montreal Cognitive Assessment score.

    Measured: Baseline, 2 years, 4 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Aug 2025
  2. Study start23 Jul 2025
  3. Primary completion30 Apr 2030 (estimated)
  4. Study completion30 Apr 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
26,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07124949
Sponsor's protocol ID
HMUIRB2024029PRE
Other IDs
ZY04JD01
Status last verified
Aug 2025
First submitted
11 Aug 2025
Last updated
20 Aug 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Li C, Liu Z, Li W, Lin Y, Hou L, Niu S, Xing Y, Huang J, Chen Y, Zhang S, Gao X, Xu Y, Wang C, Zhao Q, Liu Q, Ma W, Cai W, Gong P, Luo Y. Projecting future risk of dengue related to hydrometeorological conditions in mainland China under climate change scenarios: a modelling study. Lancet Planet Health. 2023 May;7(5):e397-e406. doi: 10.1016/S2542-5196(23)00051-7.

    PubMed 37164516

  • Goldenberg SM, Fischer F. Migration and health research: past, present, and future. BMC Public Health. 2023 Jul 25;23(1):1425. doi: 10.1186/s12889-023-16363-7.

    PubMed 37491195

  • Balsari S, Dresser C, Leaning J. Climate Change, Migration, and Civil Strife. Curr Environ Health Rep. 2020 Dec;7(4):404-414. doi: 10.1007/s40572-020-00291-4.

    PubMed 33048318

  • Ding F, Wang Q, Hao M, Maude RJ, John Day NP, Lai S, Chen S, Fang L, Ma T, Zheng C, Jiang D. Climate drives the spatiotemporal dynamics of scrub typhus in China. Glob Chang Biol. 2022 Nov;28(22):6618-6628. doi: 10.1111/gcb.16395. Epub 2022 Sep 2.

    PubMed 36056457

  • Romanello M, Napoli CD, Green C, Kennard H, Lampard P, Scamman D, Walawender M, Ali Z, Ameli N, Ayeb-Karlsson S, Beggs PJ, Belesova K, Berrang Ford L, Bowen K, Cai W, Callaghan M, Campbell-Lendrum D, Chambers J, Cross TJ, van Daalen KR, Dalin C, Dasandi N, Dasgupta S, Davies M, Dominguez-Salas P, Dubrow R, Ebi KL, Eckelman M, Ekins P, Freyberg C, Gasparyan O, Gordon-Strachan G, Graham H, Gunther SH, Hamilton I, Hang Y, Hanninen R, Hartinger S, He K, Heidecke J, Hess JJ, Hsu SC, Jamart L, Jankin S, Jay O, Kelman I, Kiesewetter G, Kinney P, Kniveton D, Kouznetsov R, Larosa F, Lee JKW, Lemke B, Liu Y, Liu Z, Lott M, Lotto Batista M, Lowe R, Odhiambo Sewe M, Martinez-Urtaza J, Maslin M, McAllister L, McMichael C, Mi Z, Milner J, Minor K, Minx JC, Mohajeri N, Momen NC, Moradi-Lakeh M, Morrissey K, Munzert S, Murray KA, Neville T, Nilsson M, Obradovich N, O'Hare MB, Oliveira C, Oreszczyn T, Otto M, Owfi F, Pearman O, Pega F, Pershing A, Rabbaniha M, Rickman J, Robinson EJZ, Rocklov J, Salas RN, Semenza JC, Sherman JD, Shumake-Guillemot J, Silbert G, Sofiev M, Springmann M, Stowell JD, Tabatabaei M, Taylor J, Thompson R, Tonne C, Treskova M, Trinanes JA, Wagner F, Warnecke L, Whitcombe H, Winning M, Wyns A, Yglesias-Gonzalez M, Zhang S, Zhang Y, Zhu Q, Gong P, Montgomery H, Costello A. The 2023 report of the Lancet Countdown on health and climate change: the imperative for a health-centred response in a world facing irreversible harms. Lancet. 2023 Dec 16;402(10419):2346-2394. doi: 10.1016/S0140-6736(23)01859-7. Epub 2023 Nov 14.

    PubMed 37977174

  • Clech L, Meister S, Belloiseau M, Benmarhnia T, Bonnet E, Casseus A, Cloos P, Dagenais C, De Allegri M, du Lou AD, Franceschin L, Goudet JM, Henrys D, Mathon D, Matin M, Queuille L, Sarker M, Turenne CP, Ridde V. Healthcare system resilience in Bangladesh and Haiti in times of global changes (climate-related events, migration and Covid-19): an interdisciplinary mixed method research protocol. BMC Health Serv Res. 2022 Mar 15;22(1):340. doi: 10.1186/s12913-021-07294-3.

    PubMed 35291985

  • Bogar K, Brensinger CM, Hennessy S, Flory JH, Bell ML, Shi C, Bilker WB, Leonard CE. Climate Change and Ambient Temperature Extremes: Association With Serious Hypoglycemia, Diabetic Ketoacidosis, and Sudden Cardiac Arrest/Ventricular Arrhythmia in People With Type 2 Diabetes. Diabetes Care. 2022 Nov 1;45(11):e171-e173. doi: 10.2337/dc22-1161. No abstract available.

    PubMed 36205432

  • Hauer ME, Jacobs SA, Kulp SA. Climate migration amplifies demographic change and population aging. Proc Natl Acad Sci U S A. 2024 Jan 16;121(3):e2206192119. doi: 10.1073/pnas.2206192119. Epub 2024 Jan 8.

    PubMed 38190539

  • Ebi KL. Managing climate change risks is imperative for human health. Nat Rev Nephrol. 2022 Feb;18(2):74-75. doi: 10.1038/s41581-021-00523-2.

    PubMed 34862513

  • Rogne T, Wang R, Wang P, Deziel NC, Metayer C, Wiemels JL, Chen K, Warren JL, Ma X. High ambient temperature in pregnancy and risk of childhood acute lymphoblastic leukaemia: an observational study. Lancet Planet Health. 2024 Jul;8(7):e506-e514. doi: 10.1016/S2542-5196(24)00121-9.

    PubMed 38969477

  • Chen H, Zhao L, Cheng L, Zhang Y, Wang H, Gu K, Bao J, Yang J, Liu Z, Huang J, Chen Y, Gao X, Xu Y, Wang C, Cai W, Gong P, Luo Y, Liang W, Huang C. Projections of heatwave-attributable mortality under climate change and future population scenarios in China. Lancet Reg Health West Pac. 2022 Sep 5;28:100582. doi: 10.1016/j.lanwpc.2022.100582. eCollection 2022 Nov.

    PubMed 36105236

  • Chen R, Yin P, Wang L, Liu C, Niu Y, Wang W, Jiang Y, Liu Y, Liu J, Qi J, You J, Kan H, Zhou M. Association between ambient temperature and mortality risk and burden: time series study in 272 main Chinese cities. BMJ. 2018 Oct 31;363:k4306. doi: 10.1136/bmj.k4306.

    PubMed 30381293

  • Diaz E, Benavente P. Contextualising the WHO Global Research Agenda on Health, Migration and Displacement in Norway invites to a reflection for decolonising research. Int J Equity Health. 2025 Mar 4;24(1):62. doi: 10.1186/s12939-025-02410-9.

    PubMed 40038573

  • Xu R, Zhao Q, Coelho MSZS, Saldiva PHN, Zoungas S, Huxley RR, Abramson MJ, Guo Y, Li S. Association between Heat Exposure and Hospitalization for Diabetes in Brazil during 2000-2015: A Nationwide Case-Crossover Study. Environ Health Perspect. 2019 Nov;127(11):117005. doi: 10.1289/EHP5688. Epub 2019 Nov 20.

    PubMed 31746643

  • Berglund B. High-altitude training. Aspects of haematological adaptation. Sports Med. 1992 Nov;14(5):289-303. doi: 10.2165/00007256-199214050-00002.

    PubMed 1439397

Questions about this trial

What is this clinical trial studying?

An observational study of Cardiovascular Diseases and Metabolic Disorders, run by Jinwei Tian at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 20 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Jinwei Tian, Ph.D. (+86 151 1451 8233, tianjinwei@hrbmu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants Experiencing First Major Cardiovascular Event (time frame: Up to 5 years from baseline). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07124949, which also lists 22 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Aug 2025; AzTrials last refreshed its copy on 6 Nov 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in